All Stories

  1. The stress–Wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches
  2. An overview of the first 5 years of the ENIGMA obsessive–compulsive disorder working group: The power of worldwide collaboration
  3. Psychiatric symptoms and expression of glucocorticoid receptor gene in cocaine users: A longitudinal study
  4. Profiling parvalbumin interneurons using iPSC: challenges and perspectives for Autism Spectrum Disorder (ASD)
  5. Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings
  6. High-resolution chromosomal microarray analysis for copy-number variations in high-functioning autism reveals large aberration typical for intellectual disability
  7. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
  8. Genome-wide Association Study of Pediatric Obsessive-Compulsive Traits: Shared Genetic Risk between Traits and Disorder
  9. Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain‐related functional pathways
  10. Common variants in Alzheimer's disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores
  11. Influence of oxytocin receptor single nucleotide sequence variants on contractility of human myometrium: an in vitro functional study
  12. New insights and perspectives on the genetics of obsessive-compulsive disorder
  13. No Association of Variants of the NPY-System With Obsessive-Compulsive Disorder in Children and Adolescents
  14. Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice
  15. Association study and a systematic meta-analysis of the VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder
  16. Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP
  17. Astrocyte- and Microglia-Specific Mitochondrial DNA Deletions Levels in Sporadic Alzheimer’s Disease
  18. The involvement of the canonical Wnt-signaling receptor LRP5 and LRP6 gene variants with ADHD and sexual dimorphism: Association study and meta-analysis
  19. Manifesto for a European research network into Problematic Usage of the Internet
  20. Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes – A Tool to Study Neurodevelopmental Disorders as ADHD
  21. Comment on the global gaming industry's statement on ICD-11 gaming disorder: a corporate strategy to disregard harm and deflect social responsibility?
  22. Glucocorticoid receptor gene variants and lower expression of NR3C1 are associated with cocaine use
  23. Neuregulin 1 (NRG1) gene expression predicts functional outcomes in individuals at clinical high-risk for psychosis
  24. Methylphenidate enhances neuronal differentiation and reduces proliferation concomitant to activation of Wnt signal transduction pathways
  25. Neurochemical markers as potential indicators of postmortem tissue quality
  26. Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits
  27. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson’s Disease Substantia Nigra
  28. A pilot investigation on DNA methylation modifications associated with complex posttraumatic symptoms in elderly traumatized in childhood
  29. High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder
  30. Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on D-Amino Acid Oxidase (DAO) Activity in Human Neuronal, Astrocyte and Kidney Cell Lines: The N-methyl D-aspartate (NMDA) Receptor Hypofunction Point of View
  31. Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder
  32. Explorative results from multistep screening for potential genetic risk loci of Alzheimer’s disease in the longitudinal VITA study cohort
  33. The impact of methylphenidate and its enantiomers on dopamine synthesis and metabolism in vitro
  34. Combining genetic and epigenetic parameters of the serotonin transporter gene in obsessive-compulsive disorder
  35. A systematic meta-analysis of the association of Neuregulin 1 (NRG1), d-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia
  36. Effects of oxytocin and arginine vasopressin on the proliferation and differentiation of a serotonergic cell line
  37. The diabetic brain and cognition
  38. Revealing the complex genetic architecture of obsessive–compulsive disorder using meta-analysis
  39. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease
  40. A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects
  41. Emerging role of miRNA in attention deficit hyperactivity disorder: a systematic review
  42. Expression of D-Amino Acid Oxidase (DAO/DAAO) and D-Amino Acid Oxidase Activator (DAOA/G72) during Development and Aging in the Human Post-mortem Brain
  43. The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension
  44. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson’s disease
  45. Neuregulin-1, D-amino acid oxidase and D-amino acid oxidase activator polymorphisms in individuals at-risk for psychosis
  46. DNA methylation profiles of elderly individuals subjected to indentured childhood labor and trauma
  47. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms
  48. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition
  49. Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics
  50. REGION-SPECIFIC REGULATION OF THE SEROTONIN 2A RECEPTOR EXPRESSION IN DEVELOPMENT AND AGING IN POSTMORTEM HUMAN BRAIN
  51. CNTNAP2 gene in high functioning autism: no association according to family and meta-analysis approaches
  52. α2A -Adrenergic receptor polymorphisms and mRNA expression levels are associated with delay discounting in cocaine users
  53. Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction
  54. Serotonin Transporter and Tryptophan Hydroxylase Gene Variations Mediate Working Memory Deficits of Cocaine Users
  55. Region-specific regulation of the serotonin 2A receptor expression in development and ageing inpost mortemhuman brain
  56. Was können Biomarker heute leisten? Über den Einsatz von Biomarkern in der psychiatrischen Diagnostik am Beispiel der ADHS
  57. Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer’s disease progression: CX3CL1, TREM2, and PPARγ
  58. Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette’s Syndrome and OCD
  59. Neurotrophin blood-based gene expression and social cognition analysis in patients with autism spectrum disorder
  60. Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer’s disease
  61. Was sind Omics?
  62. Prenatal stress increases the striatal and hippocampal expression of correlating c-FOS and serotonin transporters in murine offspring
  63. Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease
  64. Imaging genetics in obsessive-compulsive disorder: Linking genetic variations to alterations in neuroimaging
  65. P.1.g.071 Interaction between serotonin 1A and 2A receptor subtypes in neuronal and lymphoblastoid cells
  66. Trio study and meta-analysis support the association of genetic variation at the serotonin transporter with early-onset obsessive–compulsive disorder
  67. Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study
  68. Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line
  69. Copy Number Variation in Obsessive-Compulsive Disorder and Tourette Syndrome: A Cross-Disorder Study
  70. The neurobiological link between OCD and ADHD
  71. Wie biologisch sind Zwangsstörungen?
  72. Neuron-Specific Alterations in Signal Transduction Pathways associated with Alzheimer's Disease
  73. Extraordinarily Fast Response to Low-Dose Sertraline in a Child with Severe Obsessive-Compulsive Disorder and High Functioning Serotonin Transporter Genotype
  74. Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder
  75. Investigation of association of serotonin transporter and monoamine oxidase-A genes with Alzheimer's disease and depression in the VITA study cohort: A 90-month longitudinal study
  76. Aldehyde dehydrogenase 2 in sporadic Parkinson's disease
  77. Association study in siblings and case-controls of serotonin- and oxytocin-related genes with high functioning autism
  78. Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene
  79. Enhancement of cell viability after treatment with polyunsaturated fatty acids
  80. Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer´s Disease
  81. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
  82. The Loudness Dependence of Auditory Evoked Potentials (LDAEP) as an Indicator of Serotonergic Dysfunction in Patients with Predominant Schizophrenic Negative Symptoms
  83. 5-HT2A serotonin receptor agonist DOI alleviates cytotoxicity in neuroblastoma cells: Role of the ERK pathway
  84. Manifesto for a European research network into obsessive-compulsive and related disorders
  85. Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?
  86. Correction: Methylphenidate enhances neural stem cell differentiation
  87. Methylphenidate enhances neural stem cell differentiation
  88. S.08.03 New findings of copy number variations in OCD
  89. S.08.01 Potential biomarkers and genetic findings in ADHD
  90. Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study
  91. In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder
  92. Editorial
  93. Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways
  94. Pilot study: potential transcription markers for adult attention-deficit hyperactivity disorder in whole blood
  95. Alzheimer's disease and type 2 diabetes: Two diseases, one common link?
  96. Parkinson's disease: Molecular risk factors
  97. Inflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study
  98. A molecular signature in blood identifies early Parkinson’s disease
  99. 1.12.1 PARKINSON'S DISEASE: MOLECULAR RISK FACTORS
  100. Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzymegene
  101. Altered mRNA expression of monoaminergic candidate genes in the blood of children with attention deficit hyperactivity disorder and autism spectrum disorder
  102. Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer’s disease: The VITA and Milano studies
  103. d/l threo-methylphenidate enantiomers influence on catecholaminergic enzyme activities
  104. Pilot study on HTR2A promoter polymorphism, −1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessive–compulsive disorder
  105. Correlation of cognitive deficits and brain cholinesterase activity in streptozotocin-intracerebroventricularly treated rat model of sporadic alzheimer's disease
  106. Editorial
  107. Association of a Functional NOS1 Promoter Repeat with Alzheimer's Disease in the VITA Cohort
  108. Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats
  109. Brain tryptophan rather than pH-value is altered as consequence of artificial postmortem interval and storage conditions
  110. Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia
  111. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease
  112. Effects of methylphenidate: the cellular point of view
  113. PGC-1 , A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
  114. Methyl- and acetyltransferases are stable epigenetic markers postmortem
  115. The link between iron, metabolic syndrome, and Alzheimer’s disease
  116. Diabetes Type II: A Risk Factor for Depression–Parkinson–Alzheimer?
  117. Increased Mitochondrial Aldehydedehydrogenase in the putamen of individuals with Alzheimer's disease
  118. Increased xanthine oxidase in the thalamus and putamen in depression
  119. Genetics of early-onset obsessive–compulsive disorder
  120. Can enzyme kinetics of prooxidants teach us a lesson about the treatment of Alzheimer's disease: A pilot post-mortem study
  121. Chronic exogenous corticosterone administration generates an insulin-resistant brain state in rats
  122. Modeling Sporadic Alzheimer's Disease: The Insulin Resistant Brain State Generates Multiple Long-Term Morphobiological Abnormalities Including Hyperphosphorylated Tau Protein and Amyloid-β
  123. Tryptophan is a marker of human postmortem brain tissue quality
  124. P.1.d.01l Multilevel phenotyping of NOS-I knockdown mice
  125. Stress and methylphenidate treatment, both modulate neuronal activity in an animal model for ADHD
  126. Potential gene expression biomarkers in whole blood of Alzheimer's disease
  127. pH measurement as quality control on humanpost mortembrain tissue: a study of the BrainNet Europe consortium
  128. Gene Expression as Peripheral Biomarkers for Sporadic Alzheimer's Disease
  129. Genetic risk factors and markers for Alzheimer’s disease and/or depression in the VITA study
  130. Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers
  131. Trabalho de consenso de força-tarefa da WFSBP sobre marcadores biológicos das demências: contribuição da análise do LCR e do sangue para o diagnóstico precoce e diferencial das demências
  132. Commonalities in the genetics of Alzheimer’s disease and Parkinson’s disease
  133. Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: A comparative post-mortem study
  134. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements
  135. P1-347: Biomarkers for Alzheimer's disease and depression in the Vienna Transdanube Aging (VITA) study
  136. Genomic aspects of sporadic Parkinson's disease
  137. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
  138. Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70
  139. Increased xanthine oxidase in the thalamus and putamen in depression
  140. Comparison Analysis of Gene Expression Patterns between Sporadic Alzheimer's and Parkinson's Disease
  141. The effect of methylphenidate treatment on the expression of synaptic vesicle proteins in a mouse model for Attention-Deficit/Hyperactivity Disorder
  142. Methylphenidate effects on cell growth and maturation in neuronal stem cells
  143. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein
  144. Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: cDNA Microarray Studies
  145. Gene and Protein Expression Profiling in Parkinson's Disease: Quest for Neuroprotective Drugs
  146. HIV Dementia: A Neurodegenerative Disorder with Viral Etiology
  147. 1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile
  148. 1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile
  149. Biostatistical analysis of gene microarrays reveals diverse expression clusters between macaque subspecies in brain SIV infection
  150. Association study of BDNF and CNTF polymorphism to depression in non-demented subjects of the “VITA” study
  151. Insulin resistant brain state: behavioural, neurochemical and genetical resemblance to sporadic Alzheimer's disease
  152. Estrogen Receptor ?? Gene (ESR??) 3???-UTR Variants in Alzheimer Disease
  153. Association Study of the 5-HTTLPR Polymorphism and Depression in 75-Year-Old Nondemented Subjects From the Vienna Transdanube Aging (VITA) Study
  154. Serotonin transporter polymorphism and LDL-cholesterol
  155. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat
  156. The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice
  157. Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes
  158. Neuroprotective Strategies in Parkinson's Disease Using the Models of 6-Hydroxydopamine and MPTPa
  159. Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation
  160. Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70
  161. Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia
  162. Oxidative stress related markers in the “VITA” and the centenarian projects
  163. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes
  164. Gene expression profile in streptozotocin rat model for sporadic Alzheimer?s disease
  165. The benefits of microarrays as tools for studying neuropsychiatric disorders
  166. Symposia
  167. Monoamine Oxidase-B Inhibition in Alzheimer's Disease
  168. Neuroprotective Strategies in Parkinson???s Disease
  169. Early and late molecular events in neurodegeneration and neuroprotection in Parkinson’s disease MPTP model as assessed by cDNA microarray; the role of iron
  170. Monoamin-Oxidase-Hemmer
  171. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine
  172. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
  173. Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for Neuroprotection
  174. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson’s disease
  175. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine
  176. The Pivotal Role of Iron in NF-kappaB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators
  177. Apomorphine protects against MPTP-induced neurotoxicity in mice
  178. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity
  179. A hierarchical approach to vegetation classification in Kenya
  180. Behavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals